Abstract
Many patients with gastric cancer relapse during or early after adjuvant chemotherapy. The standard treatment for early relapse patients is a second-line chemotherapy (SLC) based on irinotecan, taxanes, or a platinum-based chemotherapy. The platinum-containing biweekly irinotecan plus cisplatin (IRI/CDDP) combination was assumed to be promising in several reports of clinical trials as SLC. TRICS trial, a randomized phase III study of IRI/CDDP vs. IRI in platinum-naïve gastric cancers refractory to S-1 monotherapy, revealed that both irinotecan-based chemotherapies were effective and well tolerated. This study analyzed 108 patients in the TRICS trial who experienced early relapse. Patients receiving IRI/CDDP (IRI, 60 mg/m2; CDDP, 30 mg/m2, q2w) versus IRI (150 mg/m2, q2w) were compared regarding overall survival (OS), progression-free survival (PFS), overall response rate (ORR), and safety. The OS was 14.0 (95% confidence interval [CI]: 11.0-21.2) and 14.0 (95% CI: 10.7-16.5) months for IRI/CDDP and IRI, respectively (hazard ratio [HR]: 0.782; 95% CI: 0.515-1.188, P = 0.249). No significant differences were observed for PFS (5.0 vs. 4.5 months, respectively; HR: 0.802; 95% CI: 0.543-1.185, P = 0.268) or ORR (19.6% [95% CI: 9.4-3...Continue Reading
References
Jun 8, 2001·Cancer Chemotherapy and Pharmacology·A SatoT Koda
Jan 19, 2005·British Journal of Cancer·H J KangY-K Kang
Apr 28, 2005·British Journal of Cancer·F De VitaA R Bianco
Mar 23, 2006·British Journal of Cancer·Y H ParkS H Yang
Nov 6, 2007·The New England Journal of Medicine·Shinichi SakuramotoUNKNOWN ACTS-GC Group
Oct 14, 2011·Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association·Kohei ShitaraAkira Tsuburaya
Oct 20, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Mitsuru SasakoYasuo Ohashi
Jan 10, 2012·Lancet·Yung-Jue BangUNKNOWN CLASSIC trial investigators
Nov 6, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Shuichi HironakaIchinosuke Hyodo
Dec 18, 2013·The Lancet Oncology·Hugo E R FordUNKNOWN COUGAR-02 Investigators
Feb 25, 2014·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Katsuhiko HiguchiUNKNOWN Tokyo Cooperative Oncology Group, Tokyo, Japan
Sep 23, 2014·The Lancet Oncology·Hansjochen WilkeUNKNOWN RAINBOW Study Group
Mar 24, 2015·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Kazuhiro NishikawaToshimasa Tsujinaka
Mar 10, 2016·Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association·Nozomu FuseMitsuru Sasako
Mar 1, 2018·Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association·Kazuhiro NishikawaJunichi Sakamoto
Apr 22, 2018·BMC Cancer·Seiji ItoMitsuru Sasako